We believe in the importance of sharing our research in the treatment of serious CNS conditions with the scientific community. Below are links to our most recent peer-reviewed publications including our latest data and research.

April 16, 2020

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia

February 19, 2020

Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study

August 26, 2020

Open-label titration of apomorphine sublingual film in patients with Parkinson’s disease and “OFF” episodes

June 12, 2021

Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures

November 4, 2017

Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials

May 7, 2021

Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders

September 14, 2020

Lurasidone and risk for metabolic syndrome: results from short- and long-term clinical studies in patients with schizophrenia

May 5, 2020

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study

March 2, 2017

Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment

 
 
 
 

Medical
Affairs

If you are a healthcare professional and would like more information about our research and development activities, ask a question, request to be contacted, or report an adverse event, please visit Sunovion Medical Affairs.